Olga Morales Announces Expansion of Calla Lily Care Services Inc.
Olga L. Morales, CEO of Calla Lily Care Services Inc., has announced plans to expand the organization's facilities to support more people in need, particularly through the development of a new day program for neurodivergent adults and those with intellectual and developmental differences. The initiative will provide vocational training, social engagement opportunities and community integration programs, extending services to individuals up to 55 years old.
A recent inductee of the Marquis Who's Who, Ms. Morales has long been an advocate for dignity, independence and access to comprehensive support services. As the leader of Calla Lily Care Services, she oversees administrative operations while remaining directly involved in the day-to-day care of residents.
During her years of service, Ms. Morales has worked closely with regional centers, community organizations and medical professionals to expand access to care. She has directly helped more than 60 individuals gain employment and develop greater independence, reinforcing her belief that everyone deserves the opportunity to thrive. Her ability to build long-standing relationships with staff and residents alike has been a defining factor in the growth of her facilities, and she credits her team's dedication as a key reason she can focus on expanding services to meet evolving community needs.
The planned expansion aligns with Ms. Morales' broader vision of enhancing resources for underserved communities. In addition to her work in residential care, she is the founder of VIBRANT FC, a nonprofit dedicated to supporting youth in the foster care system. Through both initiatives, she has worked to provide essential services that empower individuals to build self-sufficient lives.
Calla Lily Care Services Inc. offers structured care environments that promote personal growth and community engagement. The upcoming day program is designed to provide services for adults who have aged out of traditional programs but still require structured support.
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms worldwide. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
Align Technology Launches Integrated Consumer and Professional Brand Campaign Focused on Invisalign ® Treatment for Kids and Teens
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced integrated global professional and consumer campaigns to highlight the unique needs of growing patients and treatment options for meeting those needs and creating new smiles with the Invisalign clear aligner system. As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6. Share 'We are proud to launch these complementary Invisalign ® brand campaigns about the kid and teen-friendly orthodontic solutions from the #1 doctor-recommended clear aligner brand, 1 ' said Kamal Bhandal, senior vice president, Global Brand, Consumer and Americas Marketing. 'Our new 'Invisalign for Kids' brand consumer campaign is designed to increase awareness with parents that Invisalign aligners are an effective solution for kids and educate parents about the benefits of Invisalign treatment for kids and teens, including Invisalign ® Palatal Expander System, Invisalign First™, Invisalign ® System with mandibular advancement, as well as Invisalign ® Virtual Care to help parents monitor progress – all designed to deliver predictable results and a positive experience for growing children.' The aspects of Invisalign treatment, from Phase 1 to comprehensive Phase 2, to retention are designed for predictable results and a positive experience while addressing the unique needs of growing children. And with Invisalign aligners, children can enjoy their favorite foods, keep up their oral hygiene, maintain an active lifestyle, and smile and build their confidence. At the same time, our companion Invisalign 'Growing Patients' professional campaign provides doctors with information and awareness about the dedicated range of Invisalign treatment options designed specifically for children and teens from well-established products such as Invisalign First™ aligners to the latest additions in the growing patient product portfolio, including the Invisalign ® Palatal Expander System and Invisalign ® System with mandibular advancement featuring occlusal blocks ('MAOB'). Doctors can use the Invisalign System to treat nearly any orthodontic case, from children through teens to adults, at the different stages of their growth. Even with some baby teeth, it may be the perfect time for children ages 6 to 10 to start Phase 1 orthodontic treatment. According to the American Association of Orthodontists ('AAO'), children should get screened by an orthodontist by age 7. 2 Phase 1 treatment takes advantage of a child's normal development to help bones in the face and mouth grow correctly and reduce the need for more extensive treatment later. Once most permanent teeth are in place, Phase 2 treatment focuses on ensuring teeth are in their proper place for a healthy bite and a pleasing appearance. 3 'As kids and teens age and grow, orthodontic treatment needs to address both tooth movement and dental facial orthopedic or skeletal movement,' said Dr. Mitra Derakhshan, executive vice president, chief clinical officer, Global Treatment Planning and Clinical Services. 'As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6. I believe our new 'Invisalign for Kids' brand and 'Growing Patients' campaigns will help increase confidence in Invisalign treatment for the largest segment of the orthodontic market and drive further adoption among growing patients.' This latest announcement is part of Align's long-term investment in the growing patients' segment of the market which has included multiple innovation milestones over 20 million smiles. Overview of Invisalign products for growing patients: 2008: Invisalign ® Teen – Teen specific features to address patient compliance, natural eruption of permanent teeth, and root-movement control – issues that are common in treatment of younger patients. 2017: Invisalign ® System with mandibular advancement – the first clear aligner solution designed for simultaneous Class II correction and alignment in growing tween and teen patients and Invisalign ® System with mandibular advancement featuring enhanced precision wings. 2018: Invisalign First™ – the first clear aligner treatment with features designed specifically to address a broad range of indications in mixed-dentition patients, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion. 2023: Invisalign ® Palatal Expander System –Align's first direct 3D printed orthodontic device, provides a safe, comfortable, and clinically effective 4 alternative to traditional palatal expanders that require manually turning a screw in the device in the mouth daily to achieve skeletal expansion. 2025: Invisalign ® System with mandibular advancement featuring occlusal blocks – Align's first clear aligner product with integrated solid occlusal blocks that delivers predictable mandibular advancement. Invisalign occlusal blocks provide durability, improve engagement, and enable vertical opening to offer earlier advancement of the mandible in cases like Class II deep bite to improve treatment efficiency. 'Our commitment is to support our doctors in treating patients through every step of their journey – from first visit to a lasting smile. More than 28 years of anonymized data from more than 20 million Invisalign ® patients treated globally have helped Align develop our integrated suite of innovative products and solutions that enable doctors to treat patients over their continuum of care,' said Michael Smith, Align vice president, Product Management. 'This new integrated campaign highlights the unique product offerings within our growing patient portfolio and how we are innovating in digital orthodontics to empower doctors to transform smiles and change lives.' 1. Based on a global survey of 1,786 doctors (dentists and orthodontists who use clear aligners) by IQVIA in NA, EMEA, LATAM, and APAC. Data on File at Align Technology, as of June 30, 2022. 2. American Academy of Orthodontists. The Right Time: When Should Your Child See an Orthodontist? ( Accessed 2/26/24. 3. American Academy of Orthodontists. Embarking on a Two Phase Orthodontic Adventure ( Accessed 2/28/24. 4. Based on a survey in August 2023 in Canada of 10 Invisalign trained orthodontists who participated in the Invisalign Palatal Expander System Technical Design Assessment and have treated at least 1 patient age 6-11 years with IPE. Data on file at Align Technology, Inc. as of October 30, 2023. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Yahoo
11 hours ago
- Yahoo
Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Revenues increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024 Expect to report revenue of at least $1.7 million for quarter ending June 30, 2025, and introducing revenue guidance of $12-$16 million for the full fiscal year 2026 Submitted PMA supplement for second-generation LungFit® PH to FDA International distribution partnerships now provide access to markets representing over 2 billion lives, with LungFit® PH actively shipping to Europe, Australia, and the Middle East Appointed Robert Goodman, a commercial focused seasoned healthcare executive, to the Company's Board of Directors Conference call at 4:30 p.m. ET today, June 17th GARDEN CITY, N.Y., June 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ('Beyond Air' or the 'Company'), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for fiscal fourth quarter and year ended March 31, 2025, and provided a corporate update. 'Our commercial momentum is building, and that progress is now being reflected in our topline results,' said Steve Lisi, Chairman and Chief Executive Officer. 'With LungFit PH now installed and in regular use at more than 45 hospitals nationwide, awareness is accelerating. Clinicians and administrators are increasingly recognizing the advantages of our cylinder-free system compared to conventional nitric oxide delivery methods.' Mr. Lisi added, 'Regulatory approvals and new international partnerships across Europe, the Middle East, and Asia have already driven strong order activity, with over a dozen initial units shipped to customers in just the past few weeks. We expect to report at least $1.7 million in revenue for the quarter ending June 30, 2025, and anticipate sustained double-digit sequential revenue growth moving forward, leading to FY 2026 revenues expected to be in the range of $12 to $16 million.' 'The submission of the PMA supplement to the FDA for our second-generation LungFit PH device, which we announced yesterday, could be transformative for our business,' continued Lisi. 'If approved, we believe this new system will unlock significant market potential. Coupled with our global expansion and rising brand recognition, we are entering what we believe will be an exciting and pivotal year for Beyond Air and our shareholders.' Commercial Execution, Recent Highlights and Upcoming Milestones LungFit® PH Commercial Execution Achieved a 220% increase in annual revenue for the fiscal year ended March 31, 2025, driven by growing demand for LungFit PH through U.S. commercial activities compared to fiscal 2024. Expect revenues in first quarter of fiscal year 2026 of at least $1.7 million, which would be sequential growth of greater than 45%; and fiscal year 2026 revenue of $12 million - $16 million. Established a partnership with Vanderbilt University Medical Center (VUMC) as the first luminary site for LungFit PH, marking a major milestone in Beyond Air's mission to redefine tankless nitric oxide (iNO) delivery and drive continued innovation in respiratory care. Commenced international shipments of LungFit PH following new regulatory approvals and distribution agreements, supporting the Company's global expansion across Europe, the Middle East and Asia. Over the past few months, the Company secured several new distribution partnerships in India, Italy, Latvia, Lithuania, Estonia, Ukraine, Kuwait, Kazakhstan, Israel and Poland. As a result, the Company has more than 25 countries covered under distribution agreements, covering more than 2 billion lives. Appointed a New Board Member Appointed Robert Goodman to the Company's Board of Directors, effective June 13, 2025. Goodman is a seasoned healthcare executive and board director, with a strong track record of commercial leadership across the life sciences industry. He has held key leadership roles at a range of high-performing organizations, including BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer. Pipeline Highlights Submitted a PMA supplement for the second generation LungFit PH to U.S. FDA Published a scientific article in Annals of the American Thoracic Society that presented clinical data from the LungFit GO NTM trial which support further evaluating inhaled NO self-administered by subjects using the LungFit GO for treating NTM infections in the home. The U.S. Patent and Trademark Office (USPTO) issued a patent that provides protection for method of delivering gaseous nitric oxide (gNO) to a patient that has a condition associated with non-tuberculous mycobacteria (NTM) lung infection. Cardiac surgery PMA supplement review ongoing at FDA Currently no FDA approved nitric oxide delivery system is labeled for cardiac surgery Beyond Cancer - Solid Tumor Program Clinical Development Execution Phase 1a trial (monotherapy) - Part A of the trial evaluating ultra-high concentration Nitric Oxide (UNO) therapy in subjects with advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors at a dose of 25,000 ppm has been completed, and at the dose of 50,000 ppm is ongoing. Phase 1b trial (combination therapy) – Part B of the trial will assess the intratumoral administration of 25,000 ppm low volume (LV) Nitric Oxide (UNO) in subjects with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions, who have shown disease progression or prolonged stable disease (12 weeks) after receiving a single agent anti-PD-1 containing treatment. Timing for study initiation in Israel is under review. NeuroNOS – Autism Spectrum Disorder (ASD) Program Published a peer-reviewed medical journal article in Translational Psychiatry, which presented compelling evidence of a novel mechanism in the early stages of Alzheimer's disease (AD). These new preclinical data further underscore the consistency and power of NeuroNOS's platform. U.S. FDA granted Orphan Drug Designation to BA-102, an investigational therapy for the treatment of Phelan-McDermid Syndrome (PMS), a syndrome associated with ASD. Appointed Nobel Prize laureate, Professor Dan Shechtman, to the NeuroNOS Scientific Advisory Board Completed a $2 million equity financing in NeuroNOS from private investors as part of a larger funding round. This investment will accelerate the preclinical development of NeuroNOS's small-molecule drug, designed as an injectable or oral treatment for children with autism. Financial Results for the Fiscal Year Ended March 31, 2025 Revenues for the fiscal year ended March 31, 2025 increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024. Cost of revenue of $5.4 million was recognized for the year ended March 31, 2025, compared with $2.5 million for the year ended March 31, 2024. Cost of revenue exceeded revenue primarily driven by depreciation of LungFit devices and one-time upgrade costs to systems. Research and development expenses for the fiscal year ended March 31, 2025 were $16.9 million compared with $24.4 million for the fiscal year ended March 31, 2024. The decrease of $7.5 million was primarily attributed to a decrease in salaries, stock-based compensation and to a lesser extent from clinical and pre-clinical studies expenses. Selling, general and administrative expenses for the years ended March 31, 2025 and March 31, 2024 were $26.0 million and $37.3 million, respectively. The decrease of $11.3 million was attributed primarily to a reduction in salaries and stock-based compensation cost. Other expense for the year ended March 31, 2025 was $3.9 million compared with $1.3 million for the year ended March 31, 2024. The increase in other expense of $2.6 million was mainly due to a non-cash loss recorded upon the retirement of the Avenue Capital debt. Net loss attributed to common stockholders of Beyond Air, Inc. for the year ended March 31, 2025 was ($46.6) million or a loss of ($0.69) per share, basic and diluted, compared to a net loss attributed to common stockholders of Beyond Air, Inc. for the fiscal year ended March 31, 2024 of ($60.2) million or a loss of ($1.82) per share, basic and diluted. Cash burn in the fiscal year ended March 31, 2025, excluding the impacts of financing and the extinguishment of debt, was $44.1 million. As of March 31, 2025, the Company reported cash, cash equivalents, and marketable securities of $6.9 million, which excludes the $1.0 million payment from GETZ Healthcare that arrived after March 31, 2025, and total long-term debt outstanding of $12.2 million. Debt repayment does not begin until October 2026. Subsequent to March 31, 2025, the Company received $2.0 million of additional financing under the existing long-term debt agreement. Financial Guidance for Fiscal Year 2026: The Company expects to report revenue of at least $1.7 million for quarter ending June 30, 2025. The Company is providing revenue guidance of $12 to $16 million for the fiscal year ending March 31, 2026. Conference Call & WebcastDomestic: 1-877-407-0784 International: 1-201-689-8560 Conference ID: 13753945 Webcast: A webcast of the live conference call can be accessed by visiting the Events section of the Company's website (click here) or directly (click here). An online recording of the conference call will be available on the Company's website or via the direct link an hour after the call. About Beyond Air®, Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit About LungFit *Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting. *Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand and New Zealand. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home. About PPHNPersistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1,000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents. About Right Ventricular Dysfunction (RVD) (Indication not approved in the U.S.)Right ventricular dysfunction is a serious medical condition where the heart's right ventricular is unable to pump enough blood through the lungs to support the needs of the body, and its presence in critically ill patients is associated with significant morbidity and mortality. Numerous clinical studies showed that in the peri-operative phases of cardiac surgery, inhaled nitric oxide (iNO) is effective in decreasing pulmonary artery pressure, decreasing pulmonary vascular resistance, improving right ventricular ejection fraction, and improving blood oxygenation in the presence of pulmonary hypertension. Consequently, iNO is an important part of acutely decreasing right ventricular afterload for patients suffering from right ventricular dysfunction About Beyond Cancer, Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in subjects with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols. For more information, visit About NeuroNOSNeuroNOS is at the forefront of developing innovative treatments for neurodevelopmental and neurodegenerative disorders. The company specializes in creating therapies based on small molecules that cross the blood-brain barrier to regulate Nitric Oxide (NO) levels in the brain. Preclinical studies conducted by NeuroNOS have demonstrated that NO is present at elevated levels in children with Autism Spectrum Disorder (ASD) and adults suffering from brain-related diseases such as Alzheimer's and brain cancers. The company's research has shown that managing NO levels in the brain is crucial for maintaining normal brain function. By leveraging this groundbreaking science, NeuroNOS aims to bring transformative therapies to those affected by these challenging conditions, ultimately improving individuals' lives. Through collaborations with leading research institutions and experts in the field, the company is committed to advancing medical innovation and delivering life-changing treatments. For more information, please visit Forward Looking StatementsThis press release contains 'forward-looking statements' concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words 'appears,' 'expects,' 'plans,' 'anticipates,' 'believes' 'expects,' 'intends,' 'looks,' 'projects,' 'goal,' 'assumes,' 'targets' and similar expressions and/or the use of future tense or conditional constructions (such as 'will,' 'may,' 'could,' 'should' and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the 'Risk Factors' section of Beyond Air's most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air's website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law. CONTACTS:Investor Relations contactsCorey Davis, Advisors, LLCCdavis@ 915-2577BEYOND AIR, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(in thousands, except share data) March 31, 2025 March 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 4,665 $ 11,378 Marketable securities 2,252 23,090 Restricted cash 231 230 Accounts receivable 710 319 Inventory, net 2,417 2,127 Other current assets and prepaid expenses 5,743 6,792 Total current assets 16,018 43,936 Licensed right to use technology 1,222 1,427 Right-of-use lease assets 1,706 2,121 Property and equipment, net 11,013 9,364 Other assets 103 113 TOTAL ASSETS $ 30,062 $ 56,961 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,950 $ 1,948 Accrued expenses and other current liabilities 2,045 8,402 Operating lease liability, current portion 396 418 Loans payable, current portion 609 800 Total current liabilities 5,000 11,567 Operating lease liability, net 1,486 1,898 Long-term debt, net 9,197 14,721 Warrant liability 38 275 Derivative liability - 1,314 Total liabilities 15,721 29,775 Stockholders' equity Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding - - Common Stock, $0.0001 par value per share: 500,000,000 shares authorized, 82,570,726 and 45,900,821 shares issued and outstanding as of March 31, 2025 and 2024, respectively 8 5 Treasury stock (25 ) (25 ) Additional paid-in capital 299,982 264,780 Accumulated deficit (286,322 ) (239,697 ) Accumulated other comprehensive loss (60 ) (15 ) Total stockholders' equity attributable to Beyond Air, Inc. 13,583 25,048 Non-controlling interest 758 2,138 Total equity 14,341 27,186 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 30,062 $ 56,961 BEYOND AIR, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(amounts in thousands, except share and per share data) For the Three Months Ended For the Year Ended March 31, March 31, 2025 2024 2025 2024 (Unaudited) (Unaudited) Revenues $ 1,152 $ 470 $ 3,705 $ 1,159 Cost of revenues (1,183 ) (982 ) (5,368 ) (2,466 ) Gross loss (32 ) (512 ) (1,663 ) (1,307 ) Operating expenses: Research and development (3,258 ) (5,699 ) (16,857 ) (24,363 ) Selling, general and administrative (3,884 ) (6,423 ) (26,017 ) (37,337 ) Total Operating expenses (7,142 ) (12,122 ) (42,874 ) (61,700 ) Loss from Operations (7,174 ) (12,634 ) (44,537 ) (63,006 ) Other income (expense) Dividend/interest income 68 301 705 1,739 Interest and finance expense (580 ) (921 ) (3,019 ) (2,912 ) Change in fair value of warrant liability 18 (82 ) 237 611 Change in fair value of derivative liability - (1,099 ) 1,314 48 Foreign exchange gain/ (loss) 23 (3 ) (3 ) (6 ) Loss on extinguishment of debt 87 - (2,447 ) - Loss on disposal of fixed assets (505 ) - (738 ) - Estimated liability for contingent loss - (116 ) - (598 ) Other income / (expense) (2 ) - 9 (169 ) Total other income/ (expense) (890 ) (1,921 ) (3,942 ) (1,288 ) Net loss before income taxes $ (8,064 ) $ (14,555 ) $ (48,479 ) $ (64,295 ) Provision for income taxes - - - - Net loss $ (8,064 ) $ (14,555 ) $ (48,479 ) $ (64,295 ) Less : net loss attributable to non-controlling interest (29 ) (849 ) (1,854 ) (4,053 ) Net loss attributable to Beyond Air, Inc. (8,035 ) (13,706 ) (46,625 ) (60,242 ) Foreign currency translation loss (9 ) (49 ) (45 ) (68 ) Comprehensive loss attributable to Beyond Air, Inc. $ (8,043 ) $ (13,755 ) $ (46,670 ) $ (60,310 ) Net basic and diluted loss per share attributable to Beyond Air, Inc. $ (0.09 ) $ (0.37 ) $ (0.69 ) $ (1.82 ) Weighted average number of shares, outstanding, basic and diluted 89,979,416 37,017,375 67,706,527 33,160,180 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 hours ago
- Business Wire
Artera Achieves Nationwide Access for its ArteraAI Prostate Test with New York State License
SAN FRANCISCO--(BUSINESS WIRE)-- Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today it has received its New York laboratory permit from its Department of Health. This licensure allows Artera to offer the award-winning ArteraAI Prostate Test to one of the largest healthcare markets and makes the test available to all patients across the United States. This milestone comes on the heels of Artera's recent announcement that its test is now updated with new insights to help higher-risk patients optimize treatment decisions. This advancement was supported by newly presented validation data, which was selected for Best of ASCO 2025. The ArteraAI Prostate Test is the only test in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) that can both predict therapy benefit and forecast long-term outcomes in localized prostate cancer. Starting on June 4th, clinicians and patients in New York can access data-backed insights to personalize cancer treatment decisions. 'Receiving the New York lab license is a significant milestone for Artera,' said Andre Esteva, CEO and co-founder of Artera. 'Prostate cancer is one of the most common cancers, with the NY State Department of Health estimating that more than 15,000 men are diagnosed each year in New York alone. One of my founding goals was to increase access to AI-enabled precision medicine tools, and I'm proud our team has accomplished this in record time.' New York State inspectors examined laboratory staff qualifications, equipment, facilities, safety program, record, and overall management to ensure the highest standard of care for all laboratory patients. This license follows the College of American Pathologists (CAP) accreditation Artera received in August and the State of California license in October of last year. Together, these certifications underscore Artera's commitment to quality and patient safety. 'We are thrilled that the ArteraAI Prostate Test is now available in New York,' said Himanshu Nagar, MD, Director of Genitourinary Cancer, Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. 'This test complements existing biomarkers by integrating multimodal AI analysis of both digital pathology and clinical data, providing an additional layer of precision in risk stratification. By leveraging AI-driven insights, it enhances our ability to personalize treatment decisions, ensuring that patients receive the most appropriate therapy while minimizing unnecessary interventions.' About Artera Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Artera offers an AI-enabled test that is the first of its kind to provide both prognostic and predictive results for patients with localized prostate cancer: ArteraAI Prostate Test. Artera's multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient's biopsy and their clinical data. The AI combines this information to determine their prognosis and predict whether a patient will benefit from a particular therapy and has been validated using many Phase 3 randomized trials. Artera's laboratory is CLIA-certified and College of American Pathologists (CAP) accredited. The ArteraAI Prostate Test is clinically available through Artera's laboratory in Jacksonville, Florida, and can be ordered online at
